FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/Novo Nordisk Launches Study to Compare Efficacy of Two Cagrilintide Formulations for Obesity Treatment
研究ライブラリに戻る

Novo Nordisk Launches Study to Compare Efficacy of Two Cagrilintide Formulations for Obesity Treatment

May 25, 2026
Share
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、最近のニュースアイテムや臨床試験リストのAI補助要約です。ペプチド研究コミュニティにとって迅速でアクセスしやすい概要を提供することを目的としています。正確性のために常に下記リンク先の元のソースをご確認ください。

Novo Nordisk Launches Study to Compare Efficacy of Two Cagrilintide Formulations for Obesity Treatment

In a significant development for peptide research and obesity management, Novo Nordisk A/S has initiated a clinical study aimed at comparing two versions of cagrilintide in adults with overweight or obesity. This Phase 1 trial seeks to understand the pharmacokinetic profiles of different formulations of this promising therapeutic agent.

Background

Cagrilintide is an investigational glucagon-like peptide-2 (GLP-2) receptor antagonist that has shown promise in reducing food intake and body weight in preclinical studies. It operates by blocking the GLP-2 hormone, which stimulates appetite and nutrient absorption. The drug's potential to aid in obesity management makes it a subject of intense interest within the medical community.

Novo Nordisk, already well-known for its research into diabetes treatments like semaglutide (which has also shown efficacy in weight loss), is expanding its scope with cagrilintide. This new study aims to clarify which formulation of cagrilintide might be more effective and safer for long-term use among individuals struggling with excess weight.

Key Details

The research, officially titled "A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity," is now listed on ClinicalTrials.gov (NCT07597018). The trial will involve participants receiving either cagrilintide version D, version B, or a placebo semaglutide I. Treatment allocation will be random and double-blind to ensure unbiased results.

The study duration spans six months, during which researchers will meticulously monitor blood levels of the drug to assess its pharmacokinetic properties. This information is crucial for determining optimal dosing regimens and identifying potential side effects early on.

Key Takeaways

  • Comparative Analysis: The trial aims to compare two distinct formulations of cagrilintide to ascertain which one offers better efficacy and safety.
  • Long-term Study Design: With a study duration of six months, researchers can gain insights into the drug's long-term effects on weight management.
  • Randomized Allocation: Participants will be randomly assigned to receive either cagrilintide D or B or a placebo semaglutide I, ensuring unbiased results.
  • Pharmacokinetic Data: Comprehensive blood level monitoring over six months will provide critical pharmacokinetic data for further development of the drug.

What This Means

This study is pivotal in advancing peptide therapy for obesity management. By comparing different formulations of cagrilintide, researchers hope to identify a version that maximizes therapeutic benefits while minimizing risks. As such, this research not only contributes to the scientific understanding of GLP-2 receptor antagonists but also opens avenues for future clinical applications.

For the broader peptide community, this development underscores the ongoing commitment to discovering innovative treatments for obesity and metabolic disorders. The results from this trial could influence regulatory approvals and pave the way for new therapeutic options that address unmet medical needs in weight management.

---

Source: ClinicalTrials.gov — Published 2026-05-19

This article is for informational purposes only and does not constitute medical advice.

編集者の注

この分析はAIツールを使用して生成され、Peptide Contacts編集部がレビューしました。正確性を追求していますが、AI生成のコンテンツには誤りや省略がある可能性があります。情報確認のために常に元のソースをご確認ください。 元のソース 詳細、方法論、データについては

Peptide Contactsは、情報提供のために-curated研究要約を提供しています。このコンテンツは医療アドバイスにはなりません。健康決定をする前に常に格付けされた医療専門家に相談してください。

Comments

Sign in to join the discussion

この記事はAIを使用して生成され、誤りや省略がある可能性があります。情報提供のために提供されていますが、医療アドバイスにはなりません。常に元のソースを確認し、格付けされた医療専門家に相談してください。